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The metallo--lactamase VIM-4, mainly found in Pseudomonas aeruginosa or Acinetobacter baumannii, was
produced in Escherichia coli and characterized by biochemical and X-ray techniques. A detailed kinetic study
performed in the presence of Zn2 at concentrations ranging from 0.4 to 100 M showed that VIM-4 exhibits
a kinetic profile similar to the profiles of VIM-2 and VIM-1. However, VIM-4 is more active than VIM-1 against
benzylpenicillin, cephalothin, nitrocefin, and imipenem and is less active than VIM-2 against ampicillin
and meropenem. The crystal structure of the dizinc form of VIM-4 was solved at 1.9 Å. The sole difference
between VIM-4 and VIM-1 is found at residue 228, which is Ser in VIM-1 and Arg in VIM-4. This
substitution has a major impact on the VIM-4 catalytic efficiency compared to that of VIM-1. In contrast,
the differences between VIM-2 and VIM-4 seem to be due to a different position of the flapping loop and
two substitutions in loop 2. Study of the thermal stability and the activity of the holo- and apo-VIM-4
enzymes revealed that Zn2 ions have a pronounced stabilizing effect on the enzyme and are necessary for
preserving the structure.
First discovered in Bacillus cereus, a bacterial species of little, if
any, clinical relevance (40), metallo--lactamases (MBLs) have
rapidly emerged in opportunistic microorganisms such as Bac-
teroides fragilis and Pseudomonas aeruginosa. These enzymes
show a broad substrate spectrum, including carbapenems (2),
and are not susceptible to conventional -lactamase inactiva-
tors (37).
Despite the low level of sequence identity within the MBLs,
they share a similar fold (8). MBLs have two metal binding
sites, and the cofactors in both sites are Zn2 ions. Due to its
sequence heterogeneity, this group has been divided into three
different subclasses (B1, B2, and B3). Acquired enzymes of
subclass B1, such as SPMs, SIMs, GIMs, IMPs, and VIMs,
have been reported, among which the VIM and IMP types are
more distributed and more frequently identified. Indeed, in the
last 10 years, their production by bacteria favored major out-
breaks of nosocomial strains. To date, 24 blaVIM gene se-
quences have been deposited in GenBank, but only VIM-2 has
been biochemically and structurally characterized (13, 17). The
VIM family can be divided into five sublineages, VIM-1 (16),
VIM-2, VIM-7 (43), VIM-12 (23), and VIM-13 (21), on the
basis of their amino acid sequences.
The VIM-4 enzyme was first described in a Pseudomonas
aeruginosa isolate from the University Hospital of Thessaly
(Larissa, Greece), and this finding was followed by an outbreak
in this institution (35, 36). As blaVIM genes are carried on gene
cassettes in class 1 integrons, they can disseminate rapidly (25).
Bacteria producing VIM-4 have been reported in several coun-
tries (Greece, Italy [28], Sweden [19], Hungary [26], Poland
[33], Belgium [6], Tunisia [24], the United States, and Australia
[34]) and belong to various species (Pseudomonas aeruginosa
[19], Pseudomonas putida [6], Aeromonas spp., Enterobacter
cloacae [28], Klebsiella pneumoniae [28], and Acinetobacter bau-
mannii [18]). Libisch et al. (27) reported an outbreak of
Pseudomonas strains producing the acquired VIM-4 MBL of
seven hospitals in Hungary between October 2003 and Novem-
ber 2005.
Although a significant amount of biochemical and structural
data is available for VIM-2 (13, 17) and other important sub-
class B1 enzymes (e.g., IMP-1 and CcrA), little is known about
the functional and structural properties of VIM-4. VIM-4 differs
from VIM-1 (16) by only one amino acid substitution (S228R),
which has been hypothesized to be potentially relevant for sub-
strate binding (17). Here, we describe a detailed kinetic, biochem-
ical, and structural characterization of VIM-4 and compare its
properties to those of the VIM-1 and VIM-2 enzymes.
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Chemicals. Buffers, Chelex 100, and bovine serum albumin (BSA) were ob-
tained from Sigma-Aldrich (Steinheim, Germany). Kanamycin, ZnCl2, and tet-
racycline were purchased from Merck (Darmstadt, Germany). Imipenem was
from Merck Sharpe & Dohme Research Laboratories (Rahway, NJ), nitrocefin
was from Oxoid Ltd. (Basingstoke, United Kingdom), and ampicillin and aztreo-
nam were from S.A. Bristol-Myers Squibb (Belgium). Chloramphenicol, carben-
icillin, benzylpenicillin, and EDTA were purchased from Sigma (St. Louis, MO).
Cephalothin was from Eli Lilly Laboratories (Indianapolis, IN), cefuroxime was
from Glaxo Group Research (Greenford, United Kingdom), meropenem was a
gift from ICI Pharmaceuticals (Macclesfield, United Kingdom), biapenem was a
gift from Wyeth Lederle (Tokyo, Japan), and fura-2 was from Invitrogen (Carls-
bad, CA).
Bacterial strains, plasmids, and culture media. The blaVIM-4 gene was cloned
in a pEt9a plasmid. E. coli BL21CodonPlus(DE3) (Novagen Inc., Madison, WI)
was used as the host for metallo--lactamase gene expression. Medium compo-
nents were from Difco Laboratories (Detroit, MI).
Protein production. Protein production was performed as described by Studier
(42). The expression plasmid pET9a/VIM-4 was transformed into E. coli
BL21CodonPlus(DE3) cells. A 100-ml P 0.5G medium overnight culture of these
cells was used to inoculate 12 times 200 ml of autoinducing medium ZYP5052
supplemented with 100 g/ml kanamycin, 50 g/ml chloramphenicol, and 25
g/ml tetracycline. The cultures were grown overnight at 37°C with shaking. The
cells were collected by centrifugation, resuspended in 150 ml of 15 mM HEPES
buffer, pH 7.2 (buffer A), and lysed using a Emulsiflex C3 cell disrupter (Avestin,
Germany). The cell debris was removed by centrifugation (10,000  g for 30 min
at 4°C), and the crude protein solution was dialyzed overnight at 4°C against 15
liters of buffer A. The amount of enzyme was estimated by measuring the activity
of the crude extract against that of benzylpenicillin (final concentration, 1 mM).
Cation-adjusted Mueller-Hinton (MH) medium (agar and broth) was used to
determine MICs, as recommended by the CLSI (9).
Purification of VIM-4. The dialyzed solution was loaded onto a 150-ml ion-
exchange Q Sepharose FF column (Pharmacia Biotech) previously equilibrated
with buffer A. The elution of VIM-4 was performed using a linear NaCl gradient
(0 to 1 M) over 10 column volumes of buffer A. Fractions containing -lactamase
activity were pooled, and solid ammonium sulfate was added to yield a final
concentration of 1 M. The sample was loaded onto a butyl-Sepharose column (20
ml) (Pharmacia Biotech) previously equilibrated with buffer A containing 1 M
ammonium sulfate. VIM-4 was recovered in the flowthrough. The third purifi-
cation step consisted of size-exclusion chromatography (Sephacryl-100 column).
The final protein concentration was determined by using the molar extinction
coefficient at 280 nm (ε280  28,420 M1  cm1), calculated with the help of the
ProtParam program (ExPASy Proteomics Server, http://expasy.org/).
Electrospray ionization mass spectrometry (ESI-MS) was performed on a
Micromass (Waters) Q-TOF Ultima global Quattro Ultima apparatus on the
GIGA platform.
Determination of kinetic parameters. Hydrolysis of the substrates was moni-
tored by following the absorbance variations as described previously (29, 30),
using an Uvikon 860 spectrophotometer connected to a microcomputer via a
RS232 serial interface. To determine the Zn2 dependence of the VIM-4 activ-
ity, 1 mM benzylpenicillin was used as the substrate. Apparent dissociation
constants between Zn2 ions and VIM-4 were obtained by fitting our data with
the help of the following equation:
A
K2 K3 E0 AM K3 Zn E0 AD
K2 K3 K3 Zn Zn2
where A, AM, AD, K2, K3, E0, and [Zn] are the measured activity, the monozinc
activity, the dizinc activity, the dissociation constant of the second Zn2, the
dissociation constant of the third Zn2, the enzyme concentration, and the Zn2
concentration, respectively.
The impact of the presence of increasing concentrations of Zn2 (0, 50, and
100 M) was further analyzed using various -lactam compounds. Kinetic pa-
rameters were determined at the best Zn2 concentration. Enzyme dilutions
were prepared in a reaction buffer composed of buffer A supplemented with 20
g/ml of BSA and 50 M ZnCl2. The steady-state kinetic parameters (Km and
kcat) were determined with the integrated Henri-Michaelis equation or the
Hanes-Woolf plots. Km values below 20 M were determined as Ki values in
competition experiments with nitrocefin as the reporter substrate (11). For the
reactions characterized by high Km values, kcat/Km was calculated as described in
reference 29. The reported kcat/Km values are the means of at least three exper-
iments.
Preparation and characterization of apo-VIM-4. Apo-VIM-4 was prepared by
diluting 50 l of 40 M VIM-4 in 450 l of 20 mM HEPES, pH 7.5, 20 mM
EDTA, and 0.2 M NaCl (buffer 1). The mixture was incubated for 10 min at room
temperature and was concentrated by centrifugation to a final volume of 50 l
using a Microcon YM-10 centrifuge. Two more cycles of dilution/concentration
with buffer 1 were performed. The chelating agent was then removed by three
cycles of dilution/concentration with metal-free buffer containing 20 mM
HEPES, pH 7.5, and 1 M NaCl previously stirred in the presence of 50 g/liter
Chelex 100 (Bio-Rad Life Science Research). Two additional cycles of dilution/
concentration were performed to decrease the salt concentration using similarly
treated 20 mM HEPES, pH 8.0, and 0.2 M NaCl. The residual activity of the
enzyme was measured as described above.
The circular dichroism (CD) spectra of the holo- and apoenzymes (0.2 mg/ml)
were recorded on a Jasco J-810 spectropolarimeter. The spectra were scanned
at 25°C with a scanning speed of 20 nm/min at wavelengths ranging from 200
to 250 nm.
TSA. Thermal shift assay (TSA) experiments were carried out using an IQ5
96-well-format real-time PCR instrument (Bio-Rad) as described by Attali
et al. (1).
1H HET-SOFAST NMR. One-dimensional HET-SOFAST nuclear magnetic
resonance (NMR) experiments were performed on a DirectDrive 600 spectrom-
eter (Varian, Inc.) equipped with a triple-resonance cold probe as described by
Schanda et al. (41).
Crystallization and structure determination. Crystals were obtained at 20°C
from a mixture of 2l 5-mg/ml protein solution (10 mM HEPES, pH 7.2, 50 M
ZnCl2) and 1 l 1.55 M ammonium citrate, pH 7.0. The crystals were flash frozen
in a liquid nitrogen stream. One crystal was then exposed to X rays on the ID14-1
beam line of the European Synchrotron Radiation Facility. The diffraction data
were indexed, integrated, and scaled by using XDS software (22). Five percent of
the reflections were set aside for cross-validation. As VIM-4 differs from VIM-2
by only 12 residues, the structure of VIM-4 was solved using a molecular re-
placement approach with the Phaser program (32) and the structure of VIM-2
(Protein Data Bank accession number 1KO3) as the starting model. Several
cycles of manual rebuilding using the Coot program (15) and refinement using
the REFMAC (CCP4) program (10) were carried out. Water molecules were
added manually by examining the environment around the electron densities that
were present in both Fo  Fc and 2Fo  Fc maps, where Fo and Fc are the
observed and calculated structure-factor amplitudes for each reflection h, re-
spectively.
Protein structure accession number. Coordinates and structure factors have
been deposited in the Protein Data Bank with accession number 2whg.
RESULTS
Determination of MICs. Compared to E. coli BL21(DE3)
(pET-VIM-2), E. coli BL21(DE3)(pET-VIM-4) exhibited de-
creased susceptibility to ampicillin, narrow-spectrum cephalo-
sporins, and carbapenems. Susceptibility to those compounds
was identical between E. coli BL21(DE3)(pET-VIM-4) and E.
coli BL21(DE3)(pET-VIM-1) (Table 1).
Production and purification of VIM-4. The E. coli BL21Codon
Plus(DE3) strain, chosen to produce VIM-4, allowed produc-
TABLE 1. In vitro antimicrobial susceptibility profile of E. coli
BL21(DE3) carrying recombinant vectors in which the
















Ampicillin 	256 	256 256 1
Cephalothin 	256 	256 128 16
Cefuroxime 	256 	256 256 16
Imipenem 	32 	32 4 0.25
Meropenem 	32 	32 4 0.06
a Data for strains carrying the empty vector or carrying the cloned blaVIM-1 and
blaVIM-2 alleles are shown for comparison.













tion of 120 mg of VIM-4 per liter. Three purification steps
were needed to purify VIM-4 to homogeneity. Approximately
25 mg of purified enzyme was obtained per liter of culture
(20% overall purification yield). Upon SDS-PAGE, VIM-4
migrated with an apparent molecular mass of about 25,000 Da,
and the preparation was estimated to be 95% pure. The mo-
lecular mass of VIM-4 determined by mass spectrometry was
25,392 Da, in good agreement with the theoretical value
(25,391.2 Da).
Zn2 dependence of VIM-4 and functional properties. With
benzylpenicillin, the enzyme activity increased with the Zn2
concentration up to 50 M and was slightly inhibited at higher
concentrations (Fig. 1). For example, working at a [Zn2] of
300 M, the enzymatic activity dropped by a factor of 40%. In
fitting curve 1, we have determined the second and the third
dissociation constants of Zn2 for VIM-4. Indeed, the disso-
ciation constant of the first Zn2 (K1) was predicted to be
much lower than 1 M. We determined by inductively coupled
plasma-mass spectrometry that the protein in the absence of
added Zn2 (50 nM) was in a monozinc form; in the presence
of 50 M Zn2, the dizinc form was obtained. Thus, we can
confirm the very low dissociation constant of the first zinc
binding site (Zn1) to the enzyme, and then K1 can be negligi-
ble. We then fitted the data using a two-parameter equation
and then determined the values of K2 and K3 to be 8.5 
 2.3
M and 350 
 180 M, respectively.
The impact of the Zn2 concentration (0, 50, and 100 M)
on activity was also determined with other -lactam substrates
(Table 2). For all tested compounds, with the exception of
biapenem, the enzyme exhibited the best activity in the pres-
ence of 50 M Zn2. It is noteworthy that these conditions are
the same as those used for the characterization of VIM-1 and
VIM-2 (13, 25). The steady-state kinetic parameters (Km and
kcat) of VIM-4 were thus determined in the presence of 50 M
Zn2 (in the buffer) against a representative set of -lactam
compounds (Table 3).
VIM-4 exhibited a broad-spectrum activity profile with im-
portant differences depending on the tested substrate. As has
been observed with all MBLs described so far, only aztreonam
escaped its action. With penicillins, kcat/Km values range from
71 to 3,100 mM1  s1. The individual kinetic parameters of
VIM-4 against ampicillin could not be determined, since the
initial velocities remained proportional to the substrate con-
centrations up to 3 mM. VIM-4 was less efficient than VIM-2
against ampicillin. The catalytic efficiencies of both enzymes
were similar with benzylpenicillin, but VIM-4 was 100-fold
more efficient than VIM-1 against benzylpenicillin, thanks to
both a lower Km value and a higher kcat value. In the case of
ampicillin, despite higher Km and kcat values, the kcat/Km value
was not significantly different from that of VIM-1. With ceph-
alosporins, the Km values were low, whereas the turnover rates
exhibited higher values, so that VIM-4 was overall more effi-
cient than VIM-1 and VIM-2. Two exceptions could be ob-
served: first, the kcat/Km values for cefuroxime were similar for
VIM-4 and VIM-1, and second, VIM-4 was almost as efficient
as VIM-2 against nitrocefin. With carbapenems, the kcat/Km
ratios ranged from 230 to 23,000 mM1  s1, resulting from a
combination of low Km values and very low turnover rates, a
characteristic behavior of the VIM-type enzymes. The pH de-
pendence of the VIM-4 activity on benzylpenicillin was mea-
sured at various Zn2 concentrations (data not shown). At pH
values lower than 5, the VIM-4 enzyme is poorly active in all
tested buffers, whatever the Zn2 concentration. At pH 6,
VIM-4 exhibited maximal activity at 100 M Zn2, and at
higher Zn2 concentrations, the activity decreased. Between
pH 7 and 8, VIM-4 presented its maximal activity at 50 M
Zn2, and above 50 M Zn2, the activity gradually decreased.
At a pH of 	8, VIM-4 presented the same efficiency in the
presence of 50 to 400 M Zn2, but at 1 mM Zn2, its activity
was reduced by 50%.
VIM-4 apoenzyme. The specific activity of the apoenzyme
against benzylpenicillin was 1.2% of that of the native protein
activity at 50 M Zn2. When apo-VIM-4 and denatured apo-
VIM-4 were added with free fura-2, a chromophoric chelator,
there was no shift in fura-2 absorbance. Both spectra could be
perfectly superimposed, showing the apoenzyme to be Zn2
free. Under our experimental conditions, the apoenzyme could
not be completely reactivated. A maximum of 56% activity was
recovered upon addition of 10 Zn2 equivalents to 40 M
apoenzyme. With Ca2, Cd2, and Co2 ions, a maximum of
3% of the initial activity was recovered.
The native protein, alone or in the presence of excess Zn2,
and the apoprotein were gradually heated, and the unfolding
process was monitored with the fluorescent probe Sypro-or-










Ampicillin 1 NDb 55 8
Carbenicillin 1 ND 21.5 8
Cephalosporins
Cephalothin 0.1 3.5 35 14
Cefuroxime 0.1 1.4 7.4 4.7
Nitrocefin 0.1 15 35 19
Carbapenems
Meropenem 0.1 0.3 2.5 1.7
Biapenem 0.1 1.5 1.0 3.6
Imipenem 0.1 2.7 22 4.2
a Experiments were done in triplicate. Standard deviations were always 10%.
b ND, not determined.
FIG. 1. Influence of the Zn2 concentration on the activity of pu-
rified VIM-4 at 1 mM benzylpenicillin.













ange (Fig. 2). The native VIM-4 exhibited one transition tem-
perature (melting temperature [Tm]) at 58.5 
 0.1°C. The
addition of a 10:1 ratio of Zn2 ions to VIM-4 triggered an
important modification of the protein stability with two tran-
sitions, one at 44.4 
 0.3°C and the other one at 56.6 
 0.3°C.
The behaviors of the apo- and holoenzymes in the presence of
25 molar equivalents of EDTA showed that both unfolding
processes were identical, with a single transition at 31.8 

0.2°C, which reflected a 27°C decrease in Tms. The addition of
a 1:1 to 10:1 ratio of Zn2, Cd2, Co2, and Ca2 to the
apoenzyme form had no effect upon the stability of the protein
(data not shown).
In order to measure the degree of structure in native, metal-
free, and reactivated VIM-4, one-dimensional (1-D) HET-
SOFAST experiments were performed. VIM-4 presented a
NOE value of 0.49 (Fig. 3A), which suggested a high degree of
flexibility in solution. As underlined by the thermal shift assay,
the apoenzyme form of VIM-4 was highly destabilized; indeed,
the measured  value was 0.57. The apoenzyme form in the
presence of 5 equivalents of ZnCl2 exhibited a NOE value
(0.51) consistent with a more structured protein. The destabi-
lization of apo-VIM-4 was also confirmed by the far-UV CD
spectra of the native and apoenzyme forms, which exhibited
significant differences (Fig. 3B).
Three-dimensional structure of VIM-4. The structure of
VIM-4 in the presence of 50 M Zn2 was refined to a reso-
lution of 1.9 Å (Table 4). The crystals adopted a C-2 space
group with two molecules in the asymmetric unit. Residues 26
to 31 and 262 to 266 were not solved, as no density was observed
for them; thus, the observed polypeptide chain of VIM-4 con-
sisted of residues 32 to 261. The final model included a total of
218 water molecules, two Zn2 ions, and one citrate anion per
molecule. Figure 4 shows that VIM-4 has the typical /
fold of MBLs, consisting of a core of  sheets surrounded by 
helices. In this monomeric enzyme, two Zn2 ions are found in
the active site located at the bottom of the -sheet core. Zn1
and Zn2 had tetrahedral and hexagonal coordinations (6 li-
gands), respectively. The latter is different from the trigonal
bipyramidal coordination (5 ligands) usually observed in MBLs
(Fig. 4B). This can be explained by the presence of the citrate
anion in the active site. The water molecule that usually serves
as a bridging ligand between the two metals was replaced by a
citrate carboxylate group. Moreover, the three carboxylate
groups of citrate interacted with the side chains of the Asn231,
Phe61, Arg228, and Tyr67 residues. The MBL conserved motif
H (N/Q)116-X-H118-X-D120 and the residues that bind Zn2
ions were present in VIM-4, with the first Zn2 binding site
containing the usual three His ligands and the second site
TABLE 3. Kinetic parameters of the purified VIM-4 metallo--lactamase compared with those of VIM-1 and VIM-2a
Substrate
kcat (s1) Km (M) kcat/Km (mM1  s1)
VIM-4 VIM-1 VIM-2 VIM-19 VIM-4 VIM-1 VIM-2 VIM-19 VIM-4 VIM-1 VIM-2 VIM-19
Penicillins
Ampicillin 	210 35 125 NDb 	3,000 920 90 ND 71 38 1,400 ND
Carbenicillin 100 170 190 ND 31 75 210 ND 3,300 2,300 900 ND
Benzylpenicillin 650 30 280 1,300 180 840 70 300 3,100 36 4,000 5,000
Cephalosporins
Cephalothin 500 280 130 ND 14 55 11 ND 36,000 5,100 12,000 ND
Cefuroxime 120 330 8 ND 11 42 20 ND 6,000 7,700 400 ND
Nitrocefin 690 95 770 ND 22 17 18 ND 31,000 5,600 43,000 ND
Carbapenems
Meropenem 7 13 5 25 8 50 2 15 875 260 2,500 2,000
Biapenem 15 8.5 8.5 ND 66 7.5 15 ND 230 1,100 550 ND
Imipenem 70 0.2 34 250 3 1.5 9 40 23,000 130 3,800 6,000
Monobactam,
aztreonam
0.01 0.01 0.01 ND 	1,000 	1,000 	1,000 ND 0.01 0.01 0.01 ND
a Data for VIM-1, VIM-2, and VIM-19 are from Franceschini et al. (16), Docquier et al. (13), and Rodriguez-Martinez et al. (39), respectively. Individual kinetic
parameters are the means of three measurements. Standard deviations were always 10%.
b ND, not determined.
FIG. 2. Thermal stability of VIM-4. Thermal unfolding of 40 M
VIM-4 (heavy black line) and apo-VIM-4 (thin gray line) was followed
in the presence of Sypro-orange fluorescent probe. ZnCl2 (400 M;
thin black line) or 1 mM EDTA (heavy gray line) was added to VIM-4.
The signal of the buffer is represented by black dots. These sets of
curves are representative of three independent experiments. au, arbi-
trary units.













containing Asp120, Cys221, and His263. The other ligands in
the second site were the hydroxyl and carboxylate groups of the
citrate anion.
The native VIM-4 structure was compared to the VIM-2
structure. Consistent with the high degree of similarity in the
amino acid sequences, the overall folds of VIM-4 and VIM-2
were quite similar (root mean square deviation [RMSD], 0.545
Å). Interestingly, the Zn2 ions in VIM-2 and VIM-4 were in
identical positions, with their ligands being almost perfectly
superimposed. The RMSD value obtained from a fit including
only the atoms in a radius of 10 Å around Asp120 was 0.487 Å,
underlining the better structural conservation of the active site
than of the overall fold. Most of the 12 residues which differ in
VIM-4 and VIM-2 were in the C-terminal part of the protein
and were surface exposed (Fig. 4A). They were distant from
the active site, with the exception of the two residues at posi-
tions 223 and 224 (in loop L3). Despite identical sequences,
the so-called flapping loop (residues 58 to 68) of VIM-4 was
not positioned as it is in VIM-2, resulting in a narrower active
site in VIM-4.
Only the Ser228Arg substitution distinguished VIM-4 from
VIM-1. This substitution is located at the entry of the active-
site cavity of the protein (Fig. 5). In the case of VIM-4, the
entry is thus narrowed and positively charged compared to
VIM-1.
DISCUSSION
The study of the Zn2 dependence of VIM-4 revealed some
important features. The enzyme activity is clearly optimal at 50
M Zn2. The maximal activity is obtained between pH 7 and
8 in HEPES buffer. This feature is similar to the pH curve
obtained for the hydrolysis of benzylpenicillin and cephalospo-
rins by BcII (7). As pH and Zn2 dependence is observed for
all MBLs, it seems to be important to define standard exper-
imental conditions for comparison of their catalytic behaviors.
Inhibition at a high Zn2 concentration (300 M) was ob-
served. This is the first report highlighting inhibition of a B1
enzyme at a high Zn2 concentration. This inhibition could be
explained by nonspecific interactions between the surface of
the enzyme and the Zn2 cations, as has already been observed
for VIM-2 or other MBLs (4, 17). This Zn2 fixation could
either strongly stabilize the enzyme and impair the active-site
mobility or strongly destabilize the enzyme and disorganize the
active site.
The kinetic parameters at 50 M Zn2 confirmed the broad
activity spectrum of VIM-4, which includes all -lactam com-
FIG. 3. Comparison of the structural properties of holo- and apo-VIM-4. (A) Spectra of the reference and saturated intensities (Isat and Iref,
respectively) of the native protein from HET-SOFAST experiment of the native protein. (B) Circular dichroism spectra of the apoenzyme for
(gray) and native form (black) VIM-4 are shown. Mol. Ellip., molar ellipticity.




Apo-VIM-4 VIM-4 wild type
Data collection
X-ray source ESRF/ID14-1
Space group C 1 2 1
Cell dimensions
a, b, c (Å) 141.39, 46.22, 105.99
, ,  90.0, 105.237, 90.0
Wavelength 0.934
Resolution (Å) 47.30–1.9 (2.0–1.9)a





Completeness (%) 98.6 (95.7)
Refinement
Resolution (Å) 47.30–1.9









B factor for protein 26.52
RMSDs
Bond lengths (Å) 0.015
Bond angles (°) 1.424
a Values in parentheses refer to the highest-resolution shell.
b Rmerge  ¥ I  I/¥I, where I is the intensity of individual reflections.
c Rwork  ¥hFo  Fc/¥hFo.
d Rfree was calculated with 5% of the diffraction data selected randomly and
excluded from refinement.
e AU, arbitrary units.
f One molecule of citrate anion per molecule of VIM-4.













pounds with the exception of aztreonam. The comparison of
the kinetic parameters of VIM-1, VIM-2, and VIM-4 obtained
under the same conditions revealed that VIM-4 had similar
activity to that of VIM-2 for almost all tested substrates and
better activity than that of VIM-1. It has previously been shown
that for enzymes with the S228R substitution, e.g., VIM-2, the
Km value for ampicillin was lower than the values for the other
B1 enzymes (17). Despite this mutation, however, VIM-4 pre-
sents a high Km value for ampicillin. VIM-4 exhibits a lower Km
value for benzylpenicillin. Because benzylpenicillin and ampi-
cillin differ only by an amino group on the C-6 side chain, the
position of the flapping loop in a narrow conformation for
VIM-4 could explain this behavior. VIM-19, another VIM-1
variant, possesses two substitutions (S228R and N215K) (38).
Its catalytic efficiency toward benzylpenicillin and meropenem
was similar to that of VIM-4 (Table 3) (39). Interestingly,
VIM-4 was more efficient against imipenem. This underlines
the finding that the N215K substitution does not have a direct
impact on the broadening of the activity spectrum of MBL
enzymes.
Only a few data on the role of bound Zn2 ions on the
stability of MBLs have been collected. With the subclass B2
CphA enzyme, differences in the fluorescence emission and
circular dichroism spectra were obtained between the apo-,
mono-, and dizinc forms (20). The thermal denaturation of the
CphA apoenzyme exhibits a Tm of 45°C, which is lower than
the Tms of the mono- and dizinc forms (Tms, 55°C and 60°C,
respectively) (20). In another member of the metallo--
lactamase superfamily, glyoxalase II, Zn2 appears to be
essential for the maintenance of the native structure, as its
binding occurs during the refolding process (14). The study of
the apoenzyme confirmed the Zn2 dependence of VIM-4
stability. The addition of 1 or 2 equivalents of Zn2 ions to the
apoenzyme form of VIM-4 did not reveal any effect on the
stability or activity. This irreversibility has already been de-
scribed for some MBLs, such as for the apo-MBL from B.
fragilis, which cannot be reactivated by addition of Zn2 (12).
Likewise, the study of IMP-1 (DK4) by Juan et al. (21) and
Yamaguchi et al. (44) has revealed the impossibility to obtain
a dizinc enzyme by addition of Zn2 to the apoenzyme. The
structural differences between the apo- and dizinc forms of
VIM-4 revealed by the 1H HET-SOFAST NMR and CD ex-
periments confirm the important structural role of Zn2 in the
VIM-4 enzyme.
FIG. 4. Structure of VIM-4. (A) Three-dimensional structure of
VIM-4 enzyme. Both Zn2 ions are represented as orange spheres,
Zn2 ligands (gray or black sticks) are shown, and the locations of
the VIM-4/VIM-2 mutations are shown as meshes. (B) Active site
of the dizinc structure. Citrate and ligands are represented as sticks.
The figures were generated with the PyMOL program.
FIG. 5. Comparison of the electrostatic charges in the VIM-4 and VIM-1 active sites. Zn2 ions are represented as black spheres, and the
citrate anion is represented as green sticks. The active-site topology of the enzyme is a tunnel. The mutation is positioned at one side of the
active-site cavity, where arginine 228 is located and interacts with the citrate carboxylate.













Finally, the structure of VIM-4 confirmed an overall fold
characteristic of MBLs with an / sandwich structure. In-
terestingly, but not uncommonly, we observed a citrate anion
in the active site of the -lactamase. Citrate has been observed
in the active site of at least one member of each class of
-lactamase. In all cases, the citrate was provided by the crys-
tallization buffer and was bound to the active site. Despite
these multiple interactions, citrate did not have significant in-
hibitory activity against VIM-4 (5).
The structural comparison of VIM-1, VIM-2, and VIM-4
has revealed some interesting features. First, VIM-4 and
VIM-2 possess an arginine at position 228 in loop L3 posi-
tioned in the active-site channel. At this position, VIM-1 has a
serine with a small and noncharged lateral chain. This sole
feature is responsible for the important differences between
the individual kinetic parameters of these enzymes, with the
Km values of VIM-4 usually being lower than those of VIM-1.
Biapenem, a bulky substrate with a charged lateral chain on
C-2, cannot be strongly distorted, and this can impair its proper
positioning in the active site of VIM-4 due to the bulk and the
positive charge of the Arg228. This can explain the different
Km values of VIM-4 and VIM-1 for biapenem.
For VIM-1 and VIM-4, Lys224, a catalytically important
residue, is replaced by His224. In IMP-1 (31) and CphA (3),
the side chain of Lys224 binds to the carboxylate moiety on C-4
or C-3 of the substrate. The side chain of the histidine residue
is much shorter than that of Lys, preventing its interaction with
this carboxylate. As already proposed for VIM-2 (17), Arg228
of VIM-4, with its long side chain, may replace Lys224 and
interact with the carboxylate of -lactams. Mutations between
VIM-4 and VIM-2 are in the C-terminal part of the protein
and are mainly exposed to the solvent on the protein surface.
Only the V223I and H224Y substitutions occur close to the
active site, and both belong to loop 2. In the inhibition of
VIM-2 by the rac-2-omega-phenylpropyl-3-mercaptopropionic
acid (phenylC3SH) complex, loop 2 undergoes important
changes (44). Those two mutations (His and Val), which have
shorter side chains than Lys and Ile, may impair the interaction
between loop 2 and the substrate; thus, they may change the
affinity for some substrates. Another difference between
VIM-2 and VIM-4 is the flapping loop, which seems to be
more closed in the latter, which would decrease the accessibil-
ity to the active site for bulky antibiotics, as for biapenem, and
have an impact on catalysis.
In conclusion, this study revealed a Zn2 and pH depen-
dence of the VIM-4 enzyme, in agreement with observations
made on other subclass B1 MBLs. Our data highlight the need
to define the experimental conditions used to study MBLs.
Finally, we have proved the structural role of Zn2 on the
enzyme VIM-4, and our data suppose that VIM-4 cannot exist
as an apoenzyme in vivo, as the deletion of Zn2 is fatal to the
protein.
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